Cell Medica Begins Commercial Manufacturing of Cell Therapies

Published on: 

The Berlin-Buch facility will begin manufacture of the company’s immune cell therapy.

Cell Medica, a part of the Imperial Innovations Group, has announced that the company has started commercial manufacturing of cell therapies at its Max-Delbrück-Center of Molecular Medicine.

The company will start its commercial manufacturing operations at the Berlin-Buch, Germany facility with Cytovir CMV, an individualized immune cell therapy that treats cytomegalovirus (CMV) infections in bone marrow transplant patients. According to the company, Cytovir CMV is manufactured for each individual patient. The therapy transfers naturally occurring cytotoxic T cells from a donor to an immunosuppressed patient to reconstitute the patient’s immunity to CMV.

"The start of commercial manufacture at this facility is a significant landmark in Cell Medica's development. The facility has been designed specifically to provide high-volume, cost-efficient production of GMP-compliant patient-specific cell therapies for distribution across Europe,” Maina Bhaman, director of healthcare investments at Innovations, stated in a press release. "Cell Medica will now be able to leverage this manufacturing capability across a broad range of T-cell immunotherapy products, including both infectious disease and its exciting oncology program."


Source: Imperial Innovations